Gajanan Bhat

2.0k total citations · 1 hit paper
57 papers, 1.5k citations indexed

About

Gajanan Bhat is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gajanan Bhat has authored 57 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Gajanan Bhat's work include HER2/EGFR in Cancer Research (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Histone Deacetylase Inhibitors Research (7 papers). Gajanan Bhat is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Histone Deacetylase Inhibitors Research (7 papers). Gajanan Bhat collaborates with scholars based in United States, Netherlands and Italy. Gajanan Bhat's co-authors include Lee F. Allen, Francine M. Foss, Shanta Chawla, Poul Knoblauch, Gautham G. Shenoy, Marc B. Garnick, Andrei R. Shustov, Mark A. Socinski, Mi Rim Choi and François Lebel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Gajanan Bhat

56 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015 386 citations Owen A. O’Connor, Steven M. Horwitz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gajanan Bhat United States	19	589	546	374	344	238	57	1.5k
Allyson J. Ocean United States	18	1.1k 1.9×	477 0.9×	240 0.6×	496 1.4×	361 1.5×	81	1.9k
Yasuo Ejima Japan	20	379 0.6×	332 0.6×	171 0.5×	394 1.1×	178 0.7×	49	1.3k
Marie-Christine Étienne-Grimaldi France	27	1.3k 2.2×	722 1.3×	242 0.6×	508 1.5×	116 0.5×	82	1.9k
Laura Pizzuti Italy	23	906 1.5×	454 0.8×	140 0.4×	333 1.0×	119 0.5×	96	1.7k
Peter Hellemans Belgium	20	533 0.9×	552 1.0×	363 1.0×	148 0.4×	115 0.5×	57	1.4k
Paola Papaldo Italy	25	1.1k 1.9×	411 0.8×	93 0.2×	336 1.0×	236 1.0×	66	1.7k
Sophia Abraham United States	8	569 1.0×	832 1.5×	108 0.3×	491 1.4×	49 0.2×	12	1.6k
Morena Fasano Italy	20	680 1.2×	605 1.1×	132 0.4×	535 1.6×	74 0.3×	63	1.4k
Ulrich Jäger Austria	27	532 0.9×	535 1.0×	1.4k 3.7×	239 0.7×	88 0.4×	86	2.5k
Desirée Hao Canada	23	842 1.4×	469 0.9×	128 0.3×	633 1.8×	75 0.3×	90	1.5k

Countries citing papers authored by Gajanan Bhat

Since Specialization

Citations

This map shows the geographic impact of Gajanan Bhat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gajanan Bhat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gajanan Bhat more than expected).

Fields of papers citing papers by Gajanan Bhat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gajanan Bhat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gajanan Bhat. The network helps show where Gajanan Bhat may publish in the future.

Co-authorship network of co-authors of Gajanan Bhat

This figure shows the co-authorship network connecting the top 25 collaborators of Gajanan Bhat. A scholar is included among the top collaborators of Gajanan Bhat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gajanan Bhat. Gajanan Bhat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Le, Xiuning, Jacqulyne Robichaux, Monique B. Nilsson, et al.. (2023). 1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity. Annals of Oncology. 34. S790–S790. 2 indexed citations

Le, Xiuning, Arsela Prelaj, Christina S. Baik, et al.. (2023). MA13.09 Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies. Journal of Thoracic Oncology. 18(11). S147–S148. 1 indexed citations

Prelaj, Arsela, Gajanan Bhat, Giuseppina Calareso, et al.. (2022). Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation. Frontiers in Oncology. 12. 902967–902967. 6 indexed citations

Cornelissen, Robin, Sanyuan Sun, Marina Chiara Garassino, et al.. (2021). LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4). Annals of Oncology. 32. S1324–S1324. 6 indexed citations

Sacher, Adrian G., Xiuning Le, Robin Cornelissen, et al.. (2021). 36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. Annals of Oncology. 32. S15–S15. 19 indexed citations

Socinski, Mark A., Robin Cornelissen, Marina Chiara Garassino, et al.. (2020). LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Annals of Oncology. 31. S1188–S1188. 31 indexed citations

Sawas, Ahmed, Helen Ma, Andrei R. Shustov, et al.. (2019). Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL). Blood. 134(Supplement_1). 4050–4050. 5 indexed citations

Schiller, Gary J., et al.. (2018). High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial. Journal of Adolescent and Young Adult Oncology. 7(5). 546–552. 22 indexed citations

Verma, Ruchi, Indira Bairy, Mradul Tiwari, Gajanan Bhat, & Gautham G. Shenoy. (2018). In silico studies, synthesis and anticancer activity of novel diphenyl ether-based pyridine derivatives. Molecular Diversity. 23(3). 541–554. 14 indexed citations

10.

Karsh, Lawrence I., Neal D. Shore, Mark S. Soloway, et al.. (2018). Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 4(3). 293–301. 8 indexed citations

11.

O’Connor, Owen A., Steven M. Horwitz, Tamás Masszi, et al.. (2015). Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. Journal of Clinical Oncology. 33(23). 2492–2499. 386 indexed citations breakdown →

12.

Hari, Parameswaran, Omar S. Aljitawi, Carlos Arce‐Lara, et al.. (2015). A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Biology of Blood and Marrow Transplantation. 21(12). 2100–2105. 23 indexed citations

13.

Agarwal, Neeraj, Jordan P. McPherson, Sumati Gupta, et al.. (2015). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemotherapy and Pharmacology. 77(2). 299–308. 10 indexed citations

14.

Foss, Francine M., Ranjana H. Advani, Madeleine Duvic, et al.. (2014). A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma. British Journal of Haematology. 168(6). 811–819. 161 indexed citations

15.

Main, Michael L., et al.. (2013). Acute Mortality in Critically Ill Patients Undergoing Echocardiography With or Without an Ultrasound Contrast Agent. JACC. Cardiovascular imaging. 7(1). 40–48. 46 indexed citations

16.

Berman, Daniel S., Jamshid Maddahi, Balaji Tamarappoo, et al.. (2012). Phase II Safety and Clinical Comparison With Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease. Journal of the American College of Cardiology. 61(4). 469–477. 135 indexed citations

17.

Beer, Tomasz M., Christopher Ryan, Gajanan Bhat, & Marc B. Garnick. (2006). Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anti-Cancer Drugs. 17(9). 1075–1079. 3 indexed citations

18.

Ye, Ming, et al.. (2006). Proprietary Rel-Ease™ drug delivery technology: opportunity for sustained delivery of peptides, proteins and small molecules. Expert Opinion on Drug Delivery. 3(5). 663–675. 5 indexed citations

19.

Manna, Srimanta, et al.. (2004). Synthesis and biological evaluation of 1,3,5-trisubstituted pyrazolines bearing benzofuran. 13(3). 253–256. 16 indexed citations

20.

Shenoy, Gautham G., et al.. (2001). Synthesis and antimicrobial activities of 1,3,5 trisubstituted 2-pyrazolines. 10(3). 197–200. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact